A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)

This study is currently recruiting participants.

Verified September 2012 by Johns Hopkins University

Sponsor:

Collaborators:

Juvenile Diabetes Research Foundation

iCo Therapeutics Inc.

Information provided by (Responsible Party):

Quan Dong Nguyen, Johns Hopkins University

ClinicalTrials.gov Identifier:

NCT01565148

First received: March 15, 2012

Last updated: September 24, 2012

Last verified: September 2012

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	December 2013
Estimated Primary Completion Date:	September 2013 (Final data collection date for primary outcome measure)